Sign in
Intravitreal Gene Therapy for Neovascular AMD with ADVM-022: Results of the Phase 1 OPTIC Trial
Dante Joseph Pieramici, MD
Annual Meeting Talks
2021
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
Microscope-Integrated Optical Coherence Tomography Can Measure the Volume of Subretinal Blebs Created by a Suprachoroidal Approach
Ananth Sastry, MD
2020
Category: AMD-Neovascular